Shire Vs Allergan Brings Exclusive Contracts Out Of The Shadows (Again)
Executive Summary
Shire filed a lawsuit against Allergan, claiming that Allergan's exclusive contracting tactics for Restasis under Medicare Part D have blocked Xiidra from the market. It's the second recent suit highlighting exclusive contracts as anti-competitive.
You may also be interested in...
Allergan's Tribe Deal Over Restasis Sparks Ire From Legislators
Pharmaceutical manufacturers have been hoping to fly under Washington, D.C.'s radar, but Allergan's attempt to shield Restasis from the IPR process using a controversial deal with a Native American tribe, has led to calls for an investigation.
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
Pfizer filed a lawsuit against J&J over its efforts to block sales of Pfizer's biosimilar Inflectra through exclusive contracting for Remicade. The suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any Inflectra is reimbursed. J&J says Pfizer has failed to show the value of Inflectra.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.